Markets:

Overview

News

Currencies

International

Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Analyst Expectations For Sage Therapeutics's Future ↗

July 12, 2024

Via Benzinga

Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 11, 2024

Via Benzinga

19 Analysts Have This To Say About Sage Therapeutics ↗

June 20, 2024

Via Benzinga

Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 12, 2024

Via Benzinga

Sage Therapeutics Reports Phase 2 Huntington's Data ↗

June 11, 2024

On Tuesday before the market opened, Sage Therapeutics announced findings regarding Huntington's Disease (HD) based upon topline results from the Phase 2 SURVEYOR Study.

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics ↗

May 29, 2024

Via Benzinga

In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics ↗

April 18, 2024

Via Benzinga

Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews ↗

March 26, 2024

Via Benzinga

Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights ↗

February 28, 2024

Via Benzinga

Wall Street's Top 10 Stock Calls This Week - Sunday, June 2 ↗

June 02, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of May 27 through June 2, 2024.

Via Talk Markets

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗

May 21, 2024

Via Benzinga

SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024 ↗

April 25, 2024

SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday ↗

April 24, 2024

Via Benzinga

Earnings Scheduled For February 14, 2024 ↗

February 14, 2024

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.

Via Benzinga

The Latest Analyst Ratings for Sage Therapeutics ↗

December 12, 2023

Via Benzinga

Analyst Ratings for Sage Therapeutics ↗

November 08, 2023

Via Benzinga

Why Sage Therapeutics Stock Sank Today ↗

November 07, 2023

A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 24, 2024

Via Benzinga

Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

April 19, 2024

Via Benzinga

Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views ↗

April 17, 2024

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21....

Via Benzinga

Topics Stocks

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge ↗

April 17, 2024

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The...

Via Benzinga

Topics Stocks

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 17, 2024

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Via Benzinga

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data ↗

April 17, 2024

Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 17, 2024

Via Benzinga

Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark ↗

April 17, 2024

Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 17, 2024

Via Benzinga

J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

April 17, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Wednesday.

Via Benzinga

Topics Stocks

These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results ↗

February 15, 2024

Sage Therapeutics, Inc. (NASDAQ: SAGE) reported better-than-expected fourth-quarter revenue results on Wednesday.

Via Benzinga

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 07, 2023

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Via Benzinga

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

Headline News about Sage Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today